Hims vs Ro: Eligibility, Cost, and Provider Model Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub, this piece unpacks how two of the best-known direct-to-consumer telehealth brands handle GLP-1 weight care. Explore the full Peptides & GLP-1 library.

This review is independent and editorial. PlexusDx holds no commercial relationship with Hims, and nothing here involves affiliate links, referral fees, or sponsored placement.

Search "Hims vs Ro" and you get two recognizable names selling into the same category from slightly different starting points. Both run virtual weight programs; both can put a GLP-1 prescription in your hands without an in-person visit. This comparison walks through eligibility, what actually moves the price, the provider setup behind each, and one biological factor neither brand puts on the table.

Two household telehealth names, one clinical question

Hims & Hers Health built its audience on broad consumer wellness before adding metabolic care, while Ro (Roman Health) grew out of condition-specific men's and women's health. Where they converge is the weight-management funnel: an online questionnaire, a clinician review, and a route to medication. The branding differs more than the underlying clinical logic does.

How Hims structures its weight program

Hims operates on a subscription telehealth model. That typically bundles a virtual clinical evaluation, a provider-issued prescription, and dispensing of either an FDA-approved branded GLP-1 or a compounded semaglutide or tirzepatide prepared through a licensed compounding pharmacy. For the current program layout, check Hims's official website.

Where Ro fits in the same market

Ro also runs on subscription telehealth, and its medication menu, plan tiers, and dispensing arrangements shift over time. Rather than rely on a snapshot, confirm the live details on Ro's official website before drawing conclusions about fit.

Eligibility and the intake gate

For either brand, access starts at the intake questionnaire. You report weight, height, medical history, and current medications; a licensed clinician decides whether a GLP-1 prescription is appropriate. Neither platform hands out medication without that review. Small differences in who signs off — physician versus nurse practitioner or physician assistant — and in follow-up cadence are where the two programs quietly diverge.

Cost drivers you actually control

Across the telehealth GLP-1 market as of April 2026, monthly totals commonly land somewhere between roughly $200 and $700+, folding together program fees, the medication itself, and compounding where it applies. Both Hims and Ro publish their own numbers, and both change them. The variables that push your bill up or down are the compound chosen, the plan tier, and whether you receive a branded product or a compounded preparation — so read each brand's pricing page directly.

The compound does the work, not the logo

Whichever brand writes the script, the pharmacology comes from the molecule. GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, along with the GIP/GLP-1 dual agonist tirzepatide, act on appetite regulation, satiety signaling, and gastric emptying. The clinical record is substantial: STEP studied semaglutide for weight management (NEJM, 2021), SURMOUNT did the same for tirzepatide (NEJM, 2022), and SURMOUNT-OSA examined tirzepatide in obstructive sleep apnea (NEJM, 2024). Results differ by dose, compound, and individual.

The genetic layer neither brand maps

What neither Hims nor Ro examines is the genetic terrain a GLP-1 acts on. A variant in FTO, the fat-mass and obesity-associated gene, sits alongside GLP1R — the receptor every GLP-1 compound targets — plus MC4R in the satiety and energy-balance circuit and TCF7L2 in glucose handling. These are pathway-level markers. They describe the biology a prescriber is working within; they do not forecast how you will respond to any particular drug.

PlexusDx supplies semaglutide and tirzepatide through its Weight Management Protocols, offered as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The difference is the genetic context layered in first. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, mapping FTO, GLP1R, MC4R, and TCF7L2 so you walk into a provider conversation informed rather than guessing — the test-before-you-invest posture.

Not affiliated: PlexusDx has no affiliation or commercial tie with Hims or any company named in this article.

More from the PlexusDx library: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hims and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Weigh the PlexusDx approach: review the Weight Management Protocols for semaglutide and tirzepatide with genetic context, or begin upstream with the Precision Peptide Genetic Test.

Frequently Asked Questions

Does Hims or Ro make more sense for GLP-1 weight care?

Neither wins outright. Both run licensed telehealth funnels with comparable clinical steps, so the deciding factors are your medication preference, the plan tier you qualify for, and how each brand's follow-up fits your schedule. Compare their published details side by side before committing to either one.

Do Hims and Ro prescribe the same medications?

Both can route GLP-1 receptor agonists through telehealth, whether branded or compounded. The differences sit in dispensing pathway, subscription structure, and clinician type. The platform delivering the prescription does not change the pharmacology, which is set entirely by the compound itself rather than the logo above it.

Will the Precision Peptide Genetic Test tell me which brand to pick?

No. It does not rank telehealth brands or predict drug response. It reads pathway-level markers such as FTO, GLP1R, and MC4R that describe your baseline metabolic biology — context that stays relevant no matter which program ultimately writes your prescription or how you pay for it.

How does PlexusDx differ from both?

PlexusDx pairs semaglutide and tirzepatide protocols with upstream genetic insight from the Precision Peptide Genetic Test. That pathway-level reading of FTO, GLP1R, and MC4R variants is the piece Hims, Ro, and most telehealth-only programs leave out of the medication conversation entirely.

This article belongs to the PlexusDx Education Hub. Browse more Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.